Cargando…
Bioavailability of Epigallocatechin Gallate Administered with Different Nutritional Strategies in Healthy Volunteers
The flavanol epigallocatechin gallate (EGCG) is being tested for the treatment of several diseases in humans. However, its bioavailability and pharmacokinetic profile needs a better understanding to enable its use in clinical trials. There is no consensus on the most appropriate concentration of EGC...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278615/ https://www.ncbi.nlm.nih.gov/pubmed/32438698 http://dx.doi.org/10.3390/antiox9050440 |
_version_ | 1783543371964350464 |
---|---|
author | Andreu Fernández, Vicente Almeida Toledano, Laura Pizarro Lozano, Nieves Navarro Tapia, Elisabet Gómez Roig, María Dolores De la Torre Fornell, Rafael García Algar, Óscar |
author_facet | Andreu Fernández, Vicente Almeida Toledano, Laura Pizarro Lozano, Nieves Navarro Tapia, Elisabet Gómez Roig, María Dolores De la Torre Fornell, Rafael García Algar, Óscar |
author_sort | Andreu Fernández, Vicente |
collection | PubMed |
description | The flavanol epigallocatechin gallate (EGCG) is being tested for the treatment of several diseases in humans. However, its bioavailability and pharmacokinetic profile needs a better understanding to enable its use in clinical trials. There is no consensus on the most appropriate concentration of EGCG in the body to obtain the maximum therapeutic effects. Therefore, the aim of this study is to analyze the bioavailability of EGCG orally administered alone or with different food supplements after overnight fasting in order to determine its optimal conditions (high concentrations in blood and the lowest interindividual variations) to be used as a pharmacological tool in human trials. Ten healthy volunteers (5 men and 5 women) aged 25 to 35 years were recruited prospectively. Three series of clinical experiments with a washout period of seven days among each were performed: (1) Teavigo(®) (EGCG extract) alone, (2) Teavigo(®) with a standard breakfast, and (3) FontUp(®) (Teavigo(®) commercially prepared with fats, carbohydrates, proteins, vitamins, and minerals). Blood samples were collected at 0, 30, 60, 90, 120, 180, 240, and 360 min after EGCG intake. Free EGCG in plasma was measured using a liquid chromatography and mass spectrometry UPLC-ESI-MS/MS analytical method. The pharmacokinetic variables analyzed statistically were area under the curve (AUC(0–360)), C(max), C(av), C(min), T(1/2), and T(max). EGCG (Teavigo(®)) alone was the group with higher AUC(0–360,) C(max), and C(av) both in men (3.86 ± 4.11 µg/mL/kg/6 h; 5.95 ng/mL/kg; 2.96 ng/mL/kg) and women (3.33 ± 1.08 µg/mL/kg/6 h; 6.66 ng/mL/kg; 3.66 ng/mL). Moreover, FontUp(®) was the group with the highest value of T(1/2) both in men (192 ± 66 min) and women (133 ± 28 min). Teavigo(®) intake after fasting overnight revealed the highest concentration of EGCG in plasma according to its pharmacokinetic profile, indicating that this is an excellent alternative of administration if the experimental design requires good absorption in the gastrointestinal tract. Moreover, EGCG taken along with food supplements (FontUp(®)) improved the stability of the molecule in the body, being the best choice if the experimental design wants to reduce interindividual variation. |
format | Online Article Text |
id | pubmed-7278615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72786152020-06-12 Bioavailability of Epigallocatechin Gallate Administered with Different Nutritional Strategies in Healthy Volunteers Andreu Fernández, Vicente Almeida Toledano, Laura Pizarro Lozano, Nieves Navarro Tapia, Elisabet Gómez Roig, María Dolores De la Torre Fornell, Rafael García Algar, Óscar Antioxidants (Basel) Article The flavanol epigallocatechin gallate (EGCG) is being tested for the treatment of several diseases in humans. However, its bioavailability and pharmacokinetic profile needs a better understanding to enable its use in clinical trials. There is no consensus on the most appropriate concentration of EGCG in the body to obtain the maximum therapeutic effects. Therefore, the aim of this study is to analyze the bioavailability of EGCG orally administered alone or with different food supplements after overnight fasting in order to determine its optimal conditions (high concentrations in blood and the lowest interindividual variations) to be used as a pharmacological tool in human trials. Ten healthy volunteers (5 men and 5 women) aged 25 to 35 years were recruited prospectively. Three series of clinical experiments with a washout period of seven days among each were performed: (1) Teavigo(®) (EGCG extract) alone, (2) Teavigo(®) with a standard breakfast, and (3) FontUp(®) (Teavigo(®) commercially prepared with fats, carbohydrates, proteins, vitamins, and minerals). Blood samples were collected at 0, 30, 60, 90, 120, 180, 240, and 360 min after EGCG intake. Free EGCG in plasma was measured using a liquid chromatography and mass spectrometry UPLC-ESI-MS/MS analytical method. The pharmacokinetic variables analyzed statistically were area under the curve (AUC(0–360)), C(max), C(av), C(min), T(1/2), and T(max). EGCG (Teavigo(®)) alone was the group with higher AUC(0–360,) C(max), and C(av) both in men (3.86 ± 4.11 µg/mL/kg/6 h; 5.95 ng/mL/kg; 2.96 ng/mL/kg) and women (3.33 ± 1.08 µg/mL/kg/6 h; 6.66 ng/mL/kg; 3.66 ng/mL). Moreover, FontUp(®) was the group with the highest value of T(1/2) both in men (192 ± 66 min) and women (133 ± 28 min). Teavigo(®) intake after fasting overnight revealed the highest concentration of EGCG in plasma according to its pharmacokinetic profile, indicating that this is an excellent alternative of administration if the experimental design requires good absorption in the gastrointestinal tract. Moreover, EGCG taken along with food supplements (FontUp(®)) improved the stability of the molecule in the body, being the best choice if the experimental design wants to reduce interindividual variation. MDPI 2020-05-19 /pmc/articles/PMC7278615/ /pubmed/32438698 http://dx.doi.org/10.3390/antiox9050440 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Andreu Fernández, Vicente Almeida Toledano, Laura Pizarro Lozano, Nieves Navarro Tapia, Elisabet Gómez Roig, María Dolores De la Torre Fornell, Rafael García Algar, Óscar Bioavailability of Epigallocatechin Gallate Administered with Different Nutritional Strategies in Healthy Volunteers |
title | Bioavailability of Epigallocatechin Gallate Administered with Different Nutritional Strategies in Healthy Volunteers |
title_full | Bioavailability of Epigallocatechin Gallate Administered with Different Nutritional Strategies in Healthy Volunteers |
title_fullStr | Bioavailability of Epigallocatechin Gallate Administered with Different Nutritional Strategies in Healthy Volunteers |
title_full_unstemmed | Bioavailability of Epigallocatechin Gallate Administered with Different Nutritional Strategies in Healthy Volunteers |
title_short | Bioavailability of Epigallocatechin Gallate Administered with Different Nutritional Strategies in Healthy Volunteers |
title_sort | bioavailability of epigallocatechin gallate administered with different nutritional strategies in healthy volunteers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278615/ https://www.ncbi.nlm.nih.gov/pubmed/32438698 http://dx.doi.org/10.3390/antiox9050440 |
work_keys_str_mv | AT andreufernandezvicente bioavailabilityofepigallocatechingallateadministeredwithdifferentnutritionalstrategiesinhealthyvolunteers AT almeidatoledanolaura bioavailabilityofepigallocatechingallateadministeredwithdifferentnutritionalstrategiesinhealthyvolunteers AT pizarrolozanonieves bioavailabilityofepigallocatechingallateadministeredwithdifferentnutritionalstrategiesinhealthyvolunteers AT navarrotapiaelisabet bioavailabilityofepigallocatechingallateadministeredwithdifferentnutritionalstrategiesinhealthyvolunteers AT gomezroigmariadolores bioavailabilityofepigallocatechingallateadministeredwithdifferentnutritionalstrategiesinhealthyvolunteers AT delatorrefornellrafael bioavailabilityofepigallocatechingallateadministeredwithdifferentnutritionalstrategiesinhealthyvolunteers AT garciaalgaroscar bioavailabilityofepigallocatechingallateadministeredwithdifferentnutritionalstrategiesinhealthyvolunteers |